Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Abacus FCF Advisors LLC

Abacus FCF Advisors LLC boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 45.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 9,528 shares of the company’s stock after purchasing an additional 2,976 shares during the period. Abacus FCF Advisors LLC’s holdings in Medpace were worth $3,165,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Benjamin Edwards Inc. grew its holdings in Medpace by 232.0% during the third quarter. Benjamin Edwards Inc. now owns 1,142 shares of the company’s stock worth $381,000 after acquiring an additional 798 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Medpace in the 3rd quarter worth approximately $374,000. State Street Corp grew its stake in shares of Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock worth $251,337,000 after purchasing an additional 50,312 shares during the period. Worldquant Millennium Advisors LLC increased its holdings in shares of Medpace by 17.8% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 3,950 shares of the company’s stock valued at $1,319,000 after purchasing an additional 598 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after purchasing an additional 109,886 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the topic of several analyst reports. Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Leerink Partners assumed coverage on Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 target price on the stock. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a report on Monday, March 24th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $376.30.

Medpace Trading Up 1.0 %

MEDP stock opened at $290.10 on Tuesday. The business’s 50-day moving average is $330.36 and its 200 day moving average is $336.76. Medpace Holdings, Inc. has a 12-month low of $274.02 and a 12-month high of $459.77. The stock has a market cap of $8.77 billion, a price-to-earnings ratio of 22.97, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.